PRAMEF11: A Potential Drug Target Or Biomarker (G440560)

Target Name: PRAMEF11

NCBI ID: G440560

PRAMEF11

Other Name(s): PRA11_HUMAN | PRAME family member 11 | RP5-845O24.2

PRAMEF11: A Potential Drug Target Or Biomarker

PRAMEF11 (PRA11_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and pancreas. It is a member of the PRA11 family of proteins, which are known for their role in cell signaling and inflammation.

PRAMEF11 has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern in different tissues make it an attractive target for researchers to study and potentially develop new treatments.

One of the key challenges in studying PRAMEF11 is its complex structure. PRAMEF11 is a transmembrane protein that is composed of a catalytic center, a nucleotide-binding domain, and a cytoplasmic tail. The catalytic center is the region of the protein that contains the active site, which is responsible for catalyzing chemical reactions. The nucleotide-binding domain is the region that binds to DNA and RNA, and the cytoplasmic tail is the region that extends from the cytoplasm to the cell surface.

PRAMEF11 has been shown to play a role in a variety of cellular processes, including cell signaling, cell division, and inflammation. For example, studies have shown that PRAMEF11 is involved in the regulation of cell proliferation and differentiation, and that it plays a role in the development of cancer.

In addition to its role in cell signaling, PRAMEF11 is also a potential biomarker for a variety of diseases. Its expression has been shown to be elevated in a variety of cancer types, including breast, ovarian, and colorectal cancers. Additionally, PRAMEF11 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

Despite its potential as a drug target or biomarker, PRAMEF11 has yet to be studied in depth. There are currently no approved drugs that target PRAMEF11, and research is still in the early stages of exploring its potential applications. However, its unique structure and expression pattern make it an attractive target for researchers to study and develop new treatments for a variety of diseases.

In conclusion, PRAMEF11 is a protein that is expressed in various tissues of the human body, and its unique structure and expression pattern make it an attractive target for research and development of new treatments for a variety of diseases. Further studies are needed to fully understand its role in cell signaling and inflammation, and its potential as a drug target or biomarker.

Protein Name: PRAME Family Member 11

The "PRAMEF11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRAMEF11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets